Prediction of second-line therapy response by plasma proteins in patients with metastatic renal cell carcinoma. 6. Juni 2014 Hölters, S., Ohlmann, C., Bergmann, L., Grünwald, V., Keilholz, U., Staehler, M., Fecher-Trost, C., Schalkowsky, P., Schmerler, D., Junker, K., 2015. Plasma proteins characterize second-line therapy response in progressive renal cell carcinoma. Hölters, S., Bergmann, L., Grünwald, V., Keilholz, U., Ohlmann, C., Staehler, M., Schmerler, D., Junker, K., 2014. AACR (San Diego) 901. Weiterlesen A randomized, double-blind, placebo-controlled, multicenter, binational, phase II trial of immunotherapy with L-BLP25 (tecemotide) in patients with colorectal carcinoma following R0/R1 hepatic metastasectomy. Kasper, S., Moehler, M., Hegewisch-Becker, S., Overkamp, F., Bechstein, W.O., Kullmann, F., Lang, H., Schoen, M., Smith-Machnow, V., Seehofer, D., Voehringer, M., Geissler, M., Greil,… Weiterlesen